OptiNose plans move to U.S. after gaining $48M

OptiNose took a nontraditional approach to financing a slate of late-stage trials of its intranasal drug delivery technology. Rather than put together a new syndicate of venture groups to chip in on a new round, OptiNose ended up turning to Avista Capital Partners, a buyout firm that came up with $48.5 million. And with the fresh financing in hand, OptiNose is moving from Norway to Yardley, PA. "We characterize this as growth equity; it may be a little early for private equity," Avista's Larry Pickering tells the Wall Street Journal. "This is a very compelling device technology and it is one of the most compelling delivery technologies I've ever seen." Report